Deutsche Bank
TSHA icon

Deutsche Bank’s Taysha Gene Therapies TSHA Stock Holding History

Deutsche Bank’s Portfolio TSHA Stock Details TSHA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$813K Buy
181,769
+20,990
+13% +$97.6K ﹤0.01% 2301
2025
Q4 		$884K Buy
160,779
+37,980
+31% +$184K ﹤0.01% 2250
2025
Q3 		$402K Buy
122,799
+15,083
+14% +$42.7K ﹤0.01% 2668
2025
Q2 		$249K Sell
107,716
-26,702
-20% -$58K ﹤0.01% 2845
2025
Q1 		$187K Sell
134,418
-16,665
-11% -$27.9K ﹤0.01% 2980
2024
Q4 		$261K Sell
151,083
-2,409,201
-94% -$5M ﹤0.01% 2979
2024
Q3 		$5.15M Buy
2,560,284
+22,936
+0.9% +$50.3K ﹤0.01% 1272
2024
Q2 		$5.68M Buy
+2,537,348
New +$7.38M ﹤0.01% 1199
2022
Q2 		– Sell
-12,366
Closed -$81K – 4325
2022
Q1 		$81K Sell
12,366
-1,458
-11% -$10.9K ﹤0.01% 3654
2021
Q4 		$161K Buy
13,824
+716
+5% +$10.8K ﹤0.01% 3479
2021
Q3 		$244K Sell
13,108
-414
-3% -$7.87K ﹤0.01% 3464
2021
Q2 		$286K Buy
13,522
+7,670
+131% +$177K ﹤0.01% 3574
2021
Q1 		$119K Sell
5,852
-237
-4% -$6.42K ﹤0.01% 3884
2020
Q4 		$162K Buy
+6,089
New +$131K ﹤0.01% 3585

Other funds holding TSHA

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Deutsche Bank's TSHA Position: Q1 2026 in Review

Deutsche Bank increased its Taysha Gene Therapies (TSHA) stake by 13% in Q1 2026, buying an estimated $97.6K and bringing the position to 181,769 shares worth $813K. The position accounts for ﹤0.01% of the portfolio, ranked #2301.

Deutsche Bank first reported a position in TSHA in Q4 2020 and has held it in 14 quarters since. The position peaked at $5.68M in Q2 2024. 191 funds tracked by Wall St. Rank hold TSHA as of Q1 2026.

  • Deutsche Bank held 181,769 shares of Taysha Gene Therapies worth $813K as of Q1 2026.
  • Deutsche Bank bought 20,990 Taysha Gene Therapies shares in Q1 2026, an estimated $97.6K.
  • Taysha Gene Therapies made up ﹤0.01% of Deutsche Bank's portfolio in Q1 2026, its #2301 holding.
  • Deutsche Bank first reported a position in Taysha Gene Therapies in Q4 2020 and has held it in 14 quarters since.
  • Deutsche Bank's Taysha Gene Therapies position peaked at $5.68M in Q2 2024.
  • 191 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q1 2026.

Based on Deutsche Bank's 13F filing for Q1 2026, filed 6 May 2026.